Literature DB >> 54739

T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro.

R H Whitehead, J Thatcher, C Teasdale, G P Roberts, L E Hughes.   

Abstract

B and T lymphocytes have been measured in 100 women--71 patients with breast cancer and 29 controls--using sheep-erythrocyte rosetting techniques. Compared with controls (healthy women or patients with benign breast disease), there is a highly significant depression of T-cell percentage in all stages of breast cancer except locally advanced (stage 3) disease. These stage-3 cases seem to constitute a biologically distinct group. T-cell percentages in early (stage 1) patients overlap with those seen in stages 3 and 4, raising the possibility that there are in stage 1 two subpopulations of T-cell values that are associated with differences in subsequent tumour progression. B-lymphocyte levels are similar in all groups. Low T-cell levels return to normal after incubation with papain in virto but fall again after resuspending the treated lymphocytes in autologous (cancer) serum. The results suggest that T-cell depression is due to a masking factor on the surface of some T lymphocytes which is also present in the serum of cancer patients, and removable by enzyme digestion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 54739     DOI: 10.1016/s0140-6736(76)90085-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Post-transplant monitoring of renal allograft recipients for T, B and null lymphocyte subpopulations.

Authors:  D P Sengar; A Rashid; J E Harris
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

2.  Total T lymphocytes in primary bronchial carcinoma.

Authors:  H L Roberts; W T Donohoe; S Hewitt; D A Price Evans
Journal:  Thorax       Date:  1977-02       Impact factor: 9.139

3.  T- and B-lymphocyte subpopulations in pre-invasive and invasive carcinoma of the cervix.

Authors:  R J Rand; D M Jenkins; R Bulmer
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

4.  Sequential immunological studies on an asbestos-exposed population. I. Factors affecting peripheral blood leucocytes and T lymphocytes.

Authors:  M M Wagner; M J Campbell; R E Edwards
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

5.  Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Authors:  H S Shukla; R H Whitehead; L E Hughes
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

6.  Immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters.

Authors:  H J Wanebo; P P Rosen; T Thaler; J A Urban; H F Oettgen
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

7.  Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pre-treatment levels with reference to micrometastasis.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: a 10 year study.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.

Authors:  Lisa M Thornton; Barbara L Andersen; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2008-03-08       Impact factor: 6.968

10.  Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.

Authors:  N Thatcher; M K Palmer; N Gasiunas; D Crowther
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.